The latest news from the third batch of national picks is expected to start offering quotations on August 20th.

AuthorLooking forward to the third batch of state organizations drug centralized volume procurement of follow-up progress or in accordance with the following arrangements: July 16, Shanghai Joint Acquisition Office statistics of the amount of products reported to the State Medical Insurance Bureau;this judgment also refers to previous experience, the first round of 4 plus 7 sets of mining in December 2018 results, the following year in February-March, six months after the first 25 varieties of procurement expanded to the whole country, the second round of collection results, the results in January 2020 came out, in April into the procurement phase(Photo: Faber Technology and China Pharmaceutical Market Research Association) As of now, the progress of the third batch of national harvests is still in the closing stages of provincial reportingaccording to incomplete statistics, since the third batch of national varieties catalog published, some provinces asked for july 3 daily volume cut-off, the latest provinces to give the deadline is July 9according to Thesailan was informed that, according to the relevant requirements, in accordance with the previous two batches of accumulated experience, the collection of the amount of the collection, will be closer to the actual use of each terminalin addition to the specific schedule of collection, the final determination of collection varieties and collection rules are the most important concerns in the industryon the issue of varieties, according to the industry to judge that the possibility of change is not great, and the further optimization of the collection rules is possibleOn June 24,, the Shanghai Joint Acquisition Office held a meeting to solicit the views of some enterprises in the third batch of countries, and the rules of the third batch of national procurement were discussed on the same day: (1) the procurement cycle and the number of selected manufacturers;According to the industry to Seiber Lan said, because the number of varieties in the third batch is more, the number of manufacturers that meet the bidding conditions between varieties is also relatively large, followed by the collection of varieties, or will finely adjust the selection rules, including the number of different selected enterprises specific allocation of how much procurement volume and so oncollection category, scale or continuous expansion Although the third batch of drug collection is still in the early stages, but according to industry insiders to Saber blue, its normal momentum has emerged, for example, it is worth noting that the high-level has been emphasizing the acceleration of the establishment of a centralized band procurement normalization mechanism, gradually expand coverage, and accelerate the production of the volume from drugs to high-value medical supplies extension, this year for high-value consumables collection has startedcurrently on the national organization of drug collection, the industry recognized rules are that a variety of competitive pattern swells to more than 3, over-evaluated varieties to reach dozens of, you can carry out the volume of procurement, according to the first two rounds of the volume procurement rules of the exploration, under the national collection of the rules of winning bid, competition rules between enterprises has gradually stabilized and clearat the same time that the procurement of drugs in the state organization has entered the normal stage, there are two expansions - one is the expansion of the collection category and the other is the expansion of the procurement subjectGuo Taihong, the former president of the Zhejiang Pharmaceutical Industry Association in, told Sei-Lan that the scope of participation in the collection would be further expanded - "From a national perspective, it is expanded to all provinces, from a provincial point of view, to all cities, from the city's point of view, it may be expanded to different levels of hospitals and retail pharmacies."has already involved pilot retail pharmacies in some cities in centralized volume procurement"have more procurement subjects, only more procurement volume, so to maximize the coverage of collection is also reasonableas to the collection of products, there are industry insiders said that the follow-up collection, from the drug to expand to consumables, from the consistency evaluation of varieties extended to the non-consistent evaluation varieties, from chemical drugs to chinese medicine and even plant preparations, biological agents, etcare possible, after all, the relevant aspects continue to promote the in-depth signal of band procurement reform is clearwhile the collection of varieties and the continued expansion of the main body of participation, the sub-local, classification, batch, stratification, the formation of the city alliance and other phenomena can not be ignoredthe normalization of collection, the ecological improvement of the industry on the impact of the third batch of collection, different aspects of the judgment given are not the sameon the one hand, there are responsible for entering the third batch of collection catalog varieties of pharmaceutical representatives to Cypress Blue said that can start looking for a job, on the other hand, According to Societe Generale, the third batch of drug collection of this policy pressure brought about by the risk within the expected, is not expected to affect the pharmaceutical sector, no need to worryon the effect of the volume of procurement, the China Pharmaceutical Materials Association Research Institute Policy Research Institute issued one of the pharmaceutical industry development blue book series report "2019 pharmaceutical policy development status report" analysis pointed out that - with the consistency of the evaluation of the number of products more and more, drug centralized procurement will enter the normal operation, provincial and municipal pharmaceutical supplies will be in accordance with policy requirements, price reduction will become a trend, accelerate the rapid shuffle of enterprise shuffleis the change of product structure, the change of market pattern, the third is the change of competition mechanism, and the fourth is the change of marketing rulesthe concentration of generic drug production enterprises gradually increased, the replacement of imported products will also accelerate, circulation, pharmaceutical retailing and other industries will also be because of the transmission of policies and face new challengesSeptember 25, 2019, in the "on the national organization of drug centralized procurement pilot to expand the regional scope of the answer to reporters", the pilot office, the head of the joint procurement office on the relevant issues, said that the impact of national organization drug collection on the pharmaceutical industry is: First, through the consistency evaluation for the Standards, guide the upgrading of product structure, the second is to improve the ecology of the pharmaceutical industry, reduce the sale of enterprises with gold, purify the pharmaceutical circulation environment, improve the ecology of the pharmaceutical industry, and thirdly, to promote the large-scale development of the industry, gradually change the situation of small scale and low quality of the industry, and promote the development of industry scale, intensification and modernizationbut according to Seiber Blue understand, the relevant parties also said that only by the amount of procurement to combat the sale of gold belt is still not enough, because the range of varieties involved in the volume of procurement is still small after all, in addition to the progress of national organizations drug collection is also affected by the progress of consistency evaluation by enterprises and the use of hospital stake in the selection of varieties, the refore, the State Medical Insurance Bureau began to prepare to establish a "drug price and recruitment credit evaluation system", in a comprehensive credit evaluation, the pharmaceutical marketing chain of the various entities bound, and clear responsibility, in order to comprehensively restrict the marketing behavior of enterprisesat the same time, domestic and foreign pharmaceutical enterprises also need to make different responses according to their respective circumstances, and accordingly, the subsequent marketing model changes, organizational structure adjustment, personnel changes are inevitable.